help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alter, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alter, B. P.
The Oncologist, Vol. 1, No. 6, 361–366, December 1996
© 1996 AlphaMed Press

Aplastic Anemia, Pediatric Aspects

Blanche P. Alter

Division of Pediatric Hematology/Oncology, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA

Correspondence: Blanche P. Alter, M.D., Division of Pediatric Hematology/Oncology, The University of Texas Medical Branch at Galveston, Children’s Hospital, Room C3.270, 301 University Boulevard, Galveston, Texas 77555-0361, USA. Telephone: 409-772-2341; Fax: 409-772-4599; e-mail: blanche.alter{at}utmb.edu.

Inherited bone marrow failure syndromes (BMFs) comprise at least one-fourth of children with aplastic anemia, and perhaps up to 10% of adults. The most common syndrome is Fanconi’s anemia (FA), with more than 1,000 reported cases. FA is autosomal recessive, with birth defects in ~75% of patients. It is a DNA repair syndrome, diagnosed by finding chromosomal aberrations in cells treated with clastogenic agents. The major problems in FA are, in order, aplastic anemia, leukemia, and other cancers. There are at least five complementation groups; the gene for Group C has been cloned. Carrier identification and gene therapy are beginning in families at risk for FAC mutations. Dyskeratosis congenita (DC) is primarily X-linked (at Xq28), with autosomal recessive and dominant cases as well. Patients classically have reticulated hyperpigmented skin, dystrophic nails, and mucous membrane leukoplakia. ~50% develop aplastic anemia, sometimes prior to the DC phenotype, and ~10% develop cancer. Shwachman-Diamond syndrome consists of exocrine pancreatic insufficiency with neutropenia; ~25% develop aplastic anemia and 5%-10% develop leukemia. Amegakaryocytic thrombocytopenia presents in infancy, and often evolves into aplastic anemia and/or leukemia. Single cytopenias include Diamond-Blackfan anemia (DBA), which is inherited pure red cell aplasia; transient erythroblastopenia of childhood; Kostmann’s syndrome (KS) or infantile genetic agranulocytosis, and thrombocytopenia with absent radii in which there is neonatal thrombocytopenia and absent radii. DBA and KS, particularly the latter treated with G-CSF, may develop leukemia, and solid tumors have been reported in DBA. Treatment for the various BMFs includes bone marrow transplantation, androgens, and hematopoietic cytokines such as G-CSF. These inherited syndromes thus include various combinations of marrow failure and premalignancy.

Key Words. Aplastic anemia • Fanconi’s anemia • Dyskeratosis congenita • Shwachman-Diamond syndrome • Amegakaryocytic thrombocytopenia • Diamond-Blackfan anemia • Kostmann’s syndrome • Thrombocytopenia with absent radii • Transient erythroblastopenia of childhood







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1996 by AlphaMed Press.